OWL is a biotechnology company in the field of Metabolomics with pioneering diagnostics products and unique R&D services for the scientific community.

Metabolomics uncovers metabolic alterations in biological samples and provides an overall picture of human or animal health: The information on complex biochemical processes obtained is highly valuable in drug mechanism and toxicology studies, biomarker discovery and the optimization of biotechnological processes.

OWL´s two business lines stem from our in depth knowledge of metabolomics and liver diseases.


"OWLiver Test" is the first "in vitro" test for determining steatosis and NASH.
The company also develops diagnostic markers research for high prevalence diseases.


OWL applies its expertise in metabolomics and lipidomics to provide services to the pharmaceutical, food and cosmetics industries, as well as research centers, biotech companies and CROs.


Company introduction

  • OWLiver - information for physicians - how it works
  • owl liver for patients - that is it - benefits - faqs
  • what is metabolomics - get to know owl technology



OWL Metabolomics will be presenting new data related to innovations in NASH and NAFLD non-invasive diagnosis in clinical practice and the subtyping of NAFLD severity through metabolomics at the upcoming AASLD Liver Meeting® 2016.
OWL´s latest presentations at The AASLD Liver Meeting will consist on an oral communication and two posters. OWL will also be present at AASLD with a corporate display in the commercial exhibit space. Please plan on visiting OWL in Booth #638 during The Liver Meeting.




NuSirt Biopharma and OWL Metabolomics Partner to Advance Treatment of NASH / Non-alcoholic Steatohepatitis
Through their research collaboration, NuSirt and OWL will evaluate drug-induced lipidomic changes in human trials for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and explore the potential of developing a unique liquid-biopsy companion diagnostic (CDx) for NS-0200.




The first in vitro blood based diagnostic for Steatosis and NASH based on metabolic procedures.
Non invasive test. Allows easy follow up of patient progression.
Entirely patented and developed by OWL.


OWL is a trading name of
Parque Tecnológico de Bizkaia
Edificio 502 - Planta 0
48160 Derio - Bizkaia - Spain
Phone: +34 94 431 85 40
Fax: +34 94 431 71 40

With this web OWL intends to provide users with information to better understand their health and their diagnosed illnesses. You should consult with a
qualified physician for diagnosis and for answers to your personal questions/circunstances.
Last update: 10/20/2016

With the collaboration of: